Molecular mechanisms of inflammation. Anti-inflammatory benefits of virgin olive oil and the phenolic compound oleocanthal

Current Pharmaceutical Design

Volumn 17, Issue 8, 2011, Pages 754-768

  Lucas, Lisa ^a   Russell, Aaron ^a   Keast, Russell ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Inflammation; Mediterranean diet; Oleocanthal; Virgin olive oil phenolics

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; I KAPPA B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 7; NONSTEROID ANTIINFLAMMATORY AGENT; OLEOCANTHAL; OLIVE OIL; PHENOL DERIVATIVE; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SALICYLIC ACID; THROMBOXANE A2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CARDIOVASCULAR DISEASE; COLON CANCER; DRUG HALF LIFE; DRUG STABILITY; ENZYME PHOSPHORYLATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY DISEASE; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NONHUMAN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; STOMACH INJURY; STROKE; THERMOSTABILITY; UNSPECIFIED SIDE EFFECT;

ALDEHYDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIET, MEDITERRANEAN; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; PHENOLS; PLANT OILS; SIGNAL TRANSDUCTION;

EID: 79958239182     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428911     Document Type: Review

References (198)

1. Serhan C, Savill J, Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6(12): p. 1191-7.
2. Vane J, Botting R, Inflammation and the mechanism of action of anti-inflammatory drugs. The FASEB Journal 1987; 1(2): p. 89.
3. Packard RR, Libby P, Inflammation in atherosclerosis from vascular biology to biomarker discovery and risk prediction. ClinChem 2008; 54: p. 24-38.
4. Grivennikov S, Greten F, Karin M. Immunity, inflammation, and cancer. Cell 140(6): p. 883-99.
5. McGeer P, McGeer E, Schwab C, Inflammatory Processes Exacerbate Degenerative Neurological Disorders. Current Hypotheses and Research Milestones in Alzheimer's Disease 2009:p. 1-9.
6. Karlson E, Chibnik L, Tworoger S, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 2009; 60(3):p. 641-52.
7. Simon L, Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999; 106(5): p. 37S-42S.
8. Marnett L, Kalgutkar A, Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 1999; 20(11): p. 465-9.
9. Bardou M, Barkun AN, Preventing the gastrointestinal adverse effects of non steroidal anti-inflammatory drugs: From risk factoridentification to risk factor intervention. Joint Bone Spine 2010;77(1): p. 6-12.
10. Giugliano D, Ceriello A, Esposito K, The Effects of Diet onInflammation: Emphasis on the Metabolic Syndrome. J Am CollCardiol 2006; 48(4): p. 677-85.
11. Keys A, Coronary heart disease in seven countries. Circulation 1970; 42: p. 1-211.
12. Fung T, Rexrode K, Mantzoros C, et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009; 119(8): p. 1093.
13. Sofi F, Cesari F, Abbate R, et al. Adherence to Mediterranean dietand health status: meta-analysis. BMJ 2008; 337(sep11 2): p. a1344.
14. Fito M, Guxens M, Corella D, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med 2007; 167(11): p. 1195.
15. Trichopoulou A, Lagiou P, Kuper H, et al. Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prevent 2000; 9(9): p. 869-73.
16. La Vecchia C, Mediterranean diet and cancer. Public Health Nutr 2004; 7(7): p. 965-968.
17. Mantzoros CS, Williams CJ, Manson JE, et al. Adherence to the Mediterranean dietary pattern is positively associated with plasma adipoectin concentrations in diabetic women. Am J Clin Nutr 2006;84: p. 328-35.
18. Esposito K, Maiorino M, Di Palo C, et al. Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes mellitus. Diabetic Med 2009; 26(9): p. 900-907.
19. Giugliano D, Esposito K, Mediterranean diet and metabolic diseases. Curr Opin Lipidol 2008; 19(1): p. 63.
20. Oliviero F, Punzi L, Spinella P, Mediterranean Food Pattern in Rheumatoid Arthritis. Curr Rheumatol Rev 2009; 5(4): p. 233-40.
21. Scarmeas N, Stern Y, Mayeux R, et al. Mediterranean diet andmild cognitive impairment. Arch Neurol 2009; 66(2): p. 216.
22. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean dietpyramid: a cultural model for healthy eating. Am J Clin Nutr 1995. 61(6 Suppl): p. 1402S-1406S.
23. Hu FB, The Mediterranean diet and mortality--olive oil andbeyond. New Engl J Med 2003;348(26): p. 2595-6.
24. Stark AH, Madar Z, Olive oil as a functional food: epidemiologyand nutritional approaches. Nutr Rev 2002; 60(6): p. 170-6.
25. Galeone C, Talamini R, Levi F, et al. Fried foods, olive oil and colorectal cancer. Ann Oncol 2006;
26. Harper CR, Edwards MC, Jacobson TA, Flaxseed oil supplementation does not affect plasma lipoprotein concentrationor particle size in human subjects. J Nutr 2006; 136(11): p. 2844-8.
27. Aguilera CM, Mesa MD, Ramirez-Tortosa MC, et al. Sunflower oil does not protect against LDL oxidation as virgin olive oil does inpatients with peripheral vascular disease. Clin Nutr 2004; 23(4): p. 673-81.
28. Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: arandomized trial. Ann Intern Med 2006; 145(1): p. 1-11.
29. Salas-Salvadó J, Garcia-Arellano A, Estruch R, et al. Componentsof the Mediterranean-type food pattern and serum inflammatorymarkers among patients at high risk for cardiovascular disease. Eur J Clin Nutr 2007; 62(5): p. 651-9.
30. Fung T, McCullough M, Newby P, et al. Diet-quality scores andplasma concentrations of markers of inflammation and endothelialdysfunction. Am J Clin Nutr 2005; 82(1): p. 163.
31. Jensen M, Koh-Banerjee P, Franz M, et al. Whole grains, bran, andgerm in relation to homocysteine and markers of glycemic control,lipids, and inflammation. Am J Clin Nutr 2006; 83(2): p. 275.
32. Beauchamp GK, Keast RS, Morel D, et al. Phytochemistry:ibuprofen-like activity in extra-virgin olive oil. Nature 2005; 437:p. 45-6.
33. ano V R. Sacchi, Oleocanthal in olive oil: between myth andreality. Mol Nutr & Food Res 2006; 50(1): p. 5-6.
34. Van Bodegom D, May L, Meij H, et al. Regulation of Human Life Histories. Ann NY[35] i 2007; 1100(1): p. 84-97.
35. Lu H, Ouyang W, Huang C, Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4(4): p. 221.
36. Nathan C, Points of control in inflammation. Nature 2002;420(6917): p. 846-852.
37. Paquet P, Nikkels A, Arrese J, et al. Macrophages and TumorNecrosis Factor {alpha} in Toxic Epidermal Necrolysis. ArchDermatol 1994. 130(5): p. 605.
38. Gordon S, Taylor P, Monocyte and macrophage heterogeneity. NatRev Immunol 2005; 5(12): p. 953-64.
39. Medzhitov R, Origin and physiological roles of inflammation. Nature 2008; 454(7203): p. 428-35.
40. Germano G, Allavena P, Mantovani A, Cytokines as a keycomponent of cancer-related inflammation. Cytokine 2008; 43(3):p. 374-9.
41. Libby P, Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83(2): p. 456S.
42. Karin M, Lawrence T, Nizet V, Innate immunity gone awry:linking microbial infections to chronic inflammation and cancer. Cell 2006; 124(4): p. 823-35.
43. Pischon T, Hankinson S, Hotamisligil G, et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003;108(2): p. 155.
44. Zhao G, Etherton T, Martin K, et al. Dietary {alpha}-linolenic acidreduces inflammatory and lipid cardiovascular risk factors inhypercholesterolemic men and women. J Nutr 2004; 134(11): p. 2991.
45. Bemelmans W, Lefrandt J, Feskens E, et al. Increased -linolenicacid intake lowers C-reactive protein, but has no effect on markersof atherosclerosis. Eur J Clin Nutr 2004; 58(7): p. 1083-9.
46. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: acomprehensive perspective based on interactions between obesity,diabetes, and inflammation. Circulation 2005; 111(11): p. 1448.
47. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role off at and carbohydrate meals. J Amer Coll Cardiol 2002; 39(7): p. 1145.
48. Hedner T, Everts B, The early clinical history of salicylates inrheumatology and pain. Clin Rheumatol 1998. 17(1): p. 17-25.
49. Vane JR, Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 5: p. 231-2.
50. Liclican E, Nguyen V, Sullivan A, et al. Selective Activation of the Prostaglandin E2 Circuit is a Key Component of Chronic Injury-Induced Pathological Angiogenesis. Invest Ophthalmol Vis Sci 2010. Published ahead of print July doi: 10. 1167/iovs. 10-5455. Available from: http://www.iovs.org/content/early/2010/07/07/iovs.10-5455.full.pdf+html
51. Hata A, Breyer R, Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103(2): p. 147-66.
52. Barozzi N, Sketris I, Cooke C, et al. Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitorsuse in Australia and Nova Scotia (Canada). Br J Clin Pharmacol 2009; 68(1): p. 106-15.
53. Bertagnolli M, Zauber A, Solomon S, Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer PrevRes 2009; 2(3): p. 195.
54. Paulus H, Current medicinal approaches to the treatment ofrheumatoid arthritis. Clin Orthop 1991. 265: p. 96-102.
55. Wallace J, Vong L, NSAID-induced gastrointestinal damage andthe design of GI-sparing NSAIDs. Curr Opin Investig Drugs 2008;9(11): p. 1151-6.
56. Bombardier C, Laine L, Reicin A, et al. Comparison of uppergastrointestinal toxicity of rofecoxib and naproxen in patients withrheumatoid arthritis. New Engl J Med 2000. 343(21): p. 1520.
57. Schnitzer T, Burmester G, Mysler E, et al. Comparison oflumiracoxib with naproxen and ibuprofen in the TherapeuticArthritis Research and Gastrointestinal Event Trial (TARGET),reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364(9435): p. 665-74.
58. Goldstein J, Silverstein F, Agrawal N, et al. Reduced risk of uppergastrointestinal ulcer complications with celecoxib, a novel COX-2inhibitor. Am J gastroenterol 2000. 95(7): p. 1681-90.
59. Embase M, File D, Risk of serious NSAID-related gastrointestinalevents during long-term exposure: a systematic review. Med J Aust 2006; 6(185): p. 9.
60. Allison M, Howatson A, Torrance C, et al. Gastrointestinal damageassociated with the use of nonsteroidal antiinflammatory drugs. New Engl J Med 1992. 327(11): p. 749.
61. Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicitywith celecoxib vs nonsteroidal anti-inflammatory drugs forosteoarthritis and rheumatoid arthritis: the CLASS study: arandomized controlled trial. JAMA 2000. 284(10): p. 1247.
62. Rainsford K, Discovery, mechanisms of action and safety of ibuprofen. Int J Clin Pract 2003(135): p. 3.
63. Henry D, Lim L, Rodriguez L, et al. Variability in risk ofgastrointestinal complications with individual non-steroidal antiinflammatorydrugs: results of a collaborative meta-analysis. BMJ 1996. 312(7046): p. 1563.
64. Lanza F, Marathi U, Anand B, et al. Clinical trial: comparison ofibuprofen-phosphatidylcholine and ibuprofen on thegastrointestinal safety and analgesic efficacy in osteoarthriticpatients. Aliment Pharmacol Ther 2008; 28(4): p. 431-42.
65. Griffin M, Yared A, Ray W, Nonsteroidal antiinflammatory drugsand acute renal failure in elderly persons. Am J of Epidemiol 2000. 151(5): p. 488.
66. Lanza F, Endoscopic studies of gastric and duodenal injury afterthe use of ibuprofen, aspirin, and other nonsteroidal antiinflammatoryagents. Am J Med 1984. 77(1A): p. 19.
67. Doyle F, Berlin C, Jayawardena A, Gastrointestinal safety andtolerance of ibuprofen at maximum over-the-counter dose. AlimentPharmacol Ther 1999. 13(7): p. 897-906.
68. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapyalters {beta}-amyloid processing and deposition in an animalmodel of Alzheimer's disease. J Neurosci 2003;23(20): p. 7504.
69. Van Dam D, Coen K, De Deyn P, Ibuprofen modifies cognitivedisease progression in an Alzheimer's mouse model. J Psychopharmacol 2008;
70. Elsisi N, Darling-Reed S, Lee E, et al. Ibuprofen and apigenininduce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett 2005; 375(2): p. 91-6.
71. Agdeppa E, Kepe V, Petri A, et al. In vitro detection of (s)-naproxen and ibuprofen binding to plaques in the Alzheimer's brainusing the positron emission tomography molecular imaging probe2-(1-{6-[(2-[18F] fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene) malononitrile. Neuroscience 2003;117(3): p. 723-30.
72. Ward J, Update on ibuprofen for rheumatoid arthritis. Am J Med 1984. 77(1A): p. 3.
73. Busson M, Update on ibuprofen: review article. J Int Med Res 1986. 14(2): p. 53.
74. Banerjee M, Tripathi L, Srivastava V, et al. Modulation OfInflammatory Mediators By Ibuprofen And Curcumin TreatmentDuring Chronic Inflammation In Rat. Immunopharmacol andImmunotoxicol 2005; 25(2): p. 213-24.
75. Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. New Engl JMed 2003;348(26): p. 2599-608.
76. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease inhigh risk patients (Indo-Mediterranean Diet Heart Study): arandomised single-blind trial. Lancet 2002; 360(9344): p. 1455-61.
77. Fortes C, Forastiere F, Farchi S, et al. The protective effect of the Mediterranean diet on lung cancer. Nutr Can 2003;46(1): p. 30-7.
78. Herrera MD, Perez-Guerrero C, Marhuenda E, et al. Effects of dietary oleic-rich oils (virgin olive and high-oleic-acid sunflower)on vascular reactivity in Wistar-Kyoto and spontaneously hypertensive rats. Brit J Nutr 2001; 86(3): p. 349-57.
79. De Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999. 99(6): p. 779-85.
80. Corona G, Spencer JPE, Dessi MA, Extra virgin olive oilphenolics: absorption, metabolism, and biological activities in the GI tract. Toxicol Ind Health 2009; 25: p. 285-93.
81. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292(12): p. 1440.
82. Estruch R, Martínez-González M, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors. Ann InternMed 2006; 145(1): p. 1.
83. Fito M, Cladellas M, De la Torre R, et al. Anti-inflammatory effectof virgin olive oil in stable coronary disease patients: arandomized, crossover, controlled trial. Eur J Clin Nutr 2007; 62: p. 570-4.
84. Bogani P, Galli C, Villa M, et al. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis 2007; 190(1): p. 181-6.
85. Visioli F, Romani A, Mulinacci N, et al. Antioxidant and other biological activities of olive mill waste waters. J Agric Food Chem 1999. 47(8): p. 3397-401.
86. Konstantinidou V, Covas M, Munoz-Aguayo D, et al. In vivonutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial. The FASEB Journal.
87. Corona G, Deiana M, Incani A, et al. Inhibition of p38/CREBphosphorylation and COX-2 expression by olive oil polyphenolsunderlies their anti-proliferative effects. Biochem Biophys Res Commun 2007; 362(3): p. 606-11.
88. Khymenets O, Fitó M, Covas M, et al. Mononuclear celltranscriptome response after sustained virgin olive oil consumptionin humans: an exploratory nutrigenomics study. OMICS 2009;13(1): p. 7-19.
89. Brunelleschi S, Bardelli C, Amoruso A, et al. Minor polarcompounds extra-virgin olive oil extract (MPC-OOE) inhibits NF kappa B translocation in human monocyte/macrophages. PharmacolRes 2007; 56(6): p. 542-9.
90. Visioli F, Caruso D, Grande S, et al. Virgin Olive Oil Study(VOLOS): vasoprotective potential of extra virgin olive oil inmildly dyslipidemic patients. Eur J Nutr 2005; 44(2): p. 121-7.
91. Bellido C, Lopez-Miranda J, Blanco-Colio L, et al. Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor {kappa} B in peripheral blood mononuclearcells from healthy men. Am J Clin Nutr 2004; 80(6): p. 1487.
92. Llorente-Cortés V, Estruch R, Mena M, et al. Effect of Mediterranean diet on the expression of pro-atherogenic genes in apopulation at high cardiovascular risk. Atherosclerosis. 208(2): p. 442-50.
93. Perez-Martinez P, Lopez-Miranda J, Blanco-Colio L, et al. The chronic intake of a Mediterranean diet enriched in virgin olive oil, decreases nuclear transcription factor kappaB activation in peripheral blood mononuclear cells from healthy men. Atherosclerosis 2007; 194(2): p. e141-6.
94. Yamada P, Zarrouk M, Kawasaki K, et al. Inhibitory effect of various Tunisian olive oils on chemical mediator release and cytokine production by basophilic cells. J Ethnopharmacol 2008;116(2): p. 279-87.
95. Li H, Lin X, Positive and negative signaling components involved in TNF[alpha]-induced NF-[kappa]B activation. Cytokine 2008;41(1): p. 1-8.
96. Cicerale S, Lucas L, Keast RS, Biological activities of phenolic compounds present in virgin olive oil. Int J Mol Sci 2010. 11: p. 458-79.
97. Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugscause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1995. 92(17): p. 7961.
98. Patrono C, Rodríguez L, Cyclooxygenase-selective inhibition ofprostanoid formation: transducing biochemical selectivity intoclinical read-outs. J Clin Invest 2001; 108(1): p. 7-13.
99. Chandrasekharan N, Dai H, Roos K, et al. COX-3, acyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99(21): p. 13926.
100. Picot D, Loll P, Garavito R, The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994. 367(6460): p. 243-9.
101. Suleyman H, Demircan B, Karagoz Y, Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59(3):p. 247-58.
102. Masferrer J, Leahy K, Koki A, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000. 60(5):p. 1306.
103. Wu M, Wang C, Lin C, et al. Distinct regulation ofcyclooxygenase-2 by interleukin-1 {beta} in normal and endometriotic stromal cells. J Clin Endocrinol Metab 2005; 90(1):p. 286.
104. Howe L, Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9: p. 210-8.
105. Müller-Decker K, Fürstenberger G, The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 2007; 46(8): p. 705-710.
106. Narumiya S, Prostanoids and inflammation: a new concept arising from receptor knockout mice. J Mol Med 2009; 87(10): p. 1015-22.
107. Portanova J, Zhang Y, Anderson G, et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996. 184(3): p. 883.
108. Hinson R, Williams J, Shacter E, Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A. 1996. 93(10):p. 4885.
109. Liang X, Wang Q, Shi J, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis, Ann Neurol 2008; 64(3): p. 304-14.
110. Iacono A, Gómez R, Sperry J, et al. Effect of oleocanthal and itsderivatives on inflammatory response induced by LPS inchondrocyte cell line. Arthritis Rheum.
111. Dell'Agli M, Fagnani R, Galli GV, et al. Olive oil phenols modulate the expression of metalloproteinase 9 in THP-1 cells byacting on nuclear factor-κ B signaling. J Agric Food Chem 2010.
112. Camargo A, Ruano J, Fernandez J, et al. Gene expression change sin mononuclear cells in patients with metabolic syndrome after acute intake of phenol-rich virgin olive oil. BMC genomics. 11(1):p. 253.
113. Tak P, Firestein G, NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107(1): p. 7-12.
114. Kumar A, Takada Y, Boriek A, et al. Nuclear factor-? B: its role in health and disease. J Mol Med 2004; 82(7): p. 434-48.
115. Yamamoto Y, Gaynor R, Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. JClin Invest 2001; 107(2): p. 135-42.
116. Acharyya S, Villalta SA, Bakkar N, et al. Interplay of IKK/NF-ÎoBsignaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007;117(4): p. 889-901.
117. Pitt J, Roth W, Lacor P, et al. Alzheimer's-associated A-betaoligomers show altered structure immunoreactivity and synaptotoxicity with low doses of oleocanthal, Toxicol Appl Pharmacol 2009; doi:10. 1016/j. taap. 2009;07. 018.
118. Ma Q, Kinneer K, Ye J, et al. Inhibition of nuclear factor B byphenolic antioxidants: interplay between antioxidant signaling andinflammatory cytokine expression. Mol Pharmacol 2003;64(2): p. 211.
119. Cicerale S, Conlan X. A, Sinclair A. J, et al. Chemistry and health of olive oil phenolics. Crit Rev Food Sci Nutr 2009; 49: p. 218-36.
120. Montedoro G, Servili M, Simple and hydrolyzable compounds invirgin olive oil. Spectroscopic characterizations of the secoiridoid derivatives. J Agric Food Chem 1993. 41: p. 2228-34.
121. Andrewes P, Busch JL, de Joode T, et al. Sensory properties of virgin olive oil polyphenols: identification of deacetoxy-ligstrosideaglycon as a key contributor to pungency. J Agric Food Chem 2003;51(5): p. 1415-20.
122. Cicerale S, Breslin PAS, Beauchamp GK, et al. Sensory characterization of the irritant properties of oleocanthal, a natural anti-inflammatory agent in extra virgin olive oils. Chem Senses 2009; doi: 10. 1093/chemse/bjp006.
123. Breslin PA, Gingrich TN, Green BG, Ibuprofen as a chemesthetic stimulus: evidence of a novel mechanism of throat irritation. Chem Senses 2001; 26(1): p. 55-65.
124. Gomez-Alonso S, Fregapane G, Salvador MD, et al. Changes in phenolic composition and antioxidant activity of virgin olive oil during frying. J Agric Food Chem 2003;51(3): p. 667-72.
125. Brenes M, Garcia A, Dobarganes MC, et al. Influence of thermaltreatments simulating cooking processes on the polyphenol content in virgin olive oil. J Agric Food Chem 2002; 50(21): p. 5962-7.
126. Visioli F, et al. Olive oil phenolics are dose-dependently absorbedin humans. FEBS Letters 2000. 468(2-3): p. 159-60.
127. Caruso D, et al. Urinary excretion of olive oil phenols and their metabolites in humans. Metabolism 2001; 50(12): p. 1426-8.
128. Tuck KL, et al. The in vivo fate of hydroxytyrosol and tyrosol,antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats. J Nutr 2001; 131(7): p. 1993-6.
129. Vissers M. N, et al. Olive oil phenols are absorbed in humans. J Nutr 2002; 132(3): p. 409-17.
130. Cicerale S, Conlan X. A, Barnett NW, et al. Influence of heat on biological activity and concentration of oleocanthal- a natural anti inflammatory agent in virgin olive oil. J Agric Food Chem 2009;57: p. 1326-30.
131. Guela C, Wu C, Saroff D, et al. Aging renders the brain vulnerable to amyloid -protein neurotoxicity. Nature Med 1998. 4(7): p. 827-31.
132. 2 AmyloidProtofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Diseasease. Biochemistry 1999. 38(28): p. 8972-80.
133. Fourrier A, Letenneur L, Bégaud B, et al. Nonsteroidalantiinflammatory drug use and cognitive function in the elderly:Inconclusive results from a population-based cohort study*. J ClinEpidemiol 1996. 49(10): p. 1201.
134. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the CanadianStudy of Health and Aging. Am J Epidemiol 2002; 156(5): p. 445.
135. Zandi P, Anthony J, Hayden K, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache CountyStudy. Neurology 2002; 59(6): p. 880.
136. Vlad S, Miller D, Kowall N, et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70(19): p. 1672.
137. Szekely C, Breitner J, Fitzpatrick A, et al. NSAID use anddementia risk in the Cardiovascular Health Study*: Role of APOEand NSAID type. Neurology 2008; 70(1): p. 17.
138. Breitner J, Welsh K, Helms M, et al. Delayed onset of Alzheimer'sdisease with nonsteroidal anti-inflammatory and histamine H2blocking drugs. Neurobiol Aging 1995. 16(4): p. 523-30.
139. Yip A, Green R, Huyck M, et al. Nonsteroidal anti-inflammatorydrug use and Alzheimer's disease risk: the MIRAGE Study. BMCgeriatrics 2005; 5(1): p. 2.
140. Wolfson C, Perrault A, Moride Y, et al. A Case-Control Analysisof Nonsteroidal Anti-Inflammatory Drugs and Alzheimer'sDisease: Are They Protective? Neuroepidemiology 2000. 21(2): p. 81-6.
141. Landi F, Cesari M, Onder G, et al. Non-steroidal anti-inflammatorydrug (NSAID) use and Alzheimer disease in community-dwellingelderly patients. Am J Geriatric Psych 2003;11(2): p. 179.
142. Jantzen P, Connor K, DiCarlo G, et al. Microglial activation andbeta-amyloid deposit reduction caused by a nitric oxide-releasingnonsteroidal anti-inflammatory drug in amyloid precursor proteinplus presenilin-1 transgenic mice. J Neurosci 2002; 22(6): p. 2246.
143. Blasko I, Apochal A, Boeck G, et al. Ibuprofen decreases cytokineinducedamyloid beta production in neuronal cells. Neurobiol Dis 2001; 8(6): p. 1094-101.
144. McKee A, Carreras I, Hossain L, et al. Ibuprofen reduces A [beta],hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008; 1207: p. 225-36.
145. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet,and risk of Alzheimer disease. JAMA 2009; 302: p. 627-37.
146. Scarmeas N, Stern Y, Mayeux R, et al. Mediterranean diet,Alzheimer disease, and vascular mediation. Arch neurol 2006: p. 63. 12.
147. Li W, Sperry JB, Crowe A, et al. Inhibition of tau fibrillization byoleocanthal via reaction with amino groups of tau. J Neurochem 2009; 110: p. 1339-51.
148. McKellar G, Morrison E, McEntegart A, et al. A pilot study of aMediterranean-type diet intervention in female patients withrheumatoid arthritis living in areas of social deprivation in Glasgow. BMJ 2007; 66(9): p. 1239.
149. Sköldstam L, Hagfors L, Johansson G, An experimental study of aMediterranean diet intervention for patients with rheumatoidarthritis. Ann Rheum Dis 2003;62(3): p. 208.
150. Linos A, Kaklamani V. G, Kaklamani E, et al. Dietary factors inrelation to rheumatoid arthritis: a role for olive oil and cookedvegetables? Am J Clin Nutr 1999. 70(6): p. 1077-82.
151. Martinínez-Domínguez E, De la Puerta R, Ruiz-Gutierrez V, Protective effects upon experimental inflammation models of apolyphenol-supplemented virgin olive oil diet. Inflamm Res 2001;50(2): p. 102-6.
152. Tetlow L, Adlam D, Woolley D, Matrix metalloproteinase andproinflammatory cytokine production by chondrocytes of humanosteoarthritic cartilage: associations with degenerative changes. ArthritisRheum 2001; 44(3): p. 585-94.
153. Scher J, Pillinger M, Abramson S, Nitric oxide synthases andosteoarthritis. Curr Rheumatol Rep 2007; 9(1): p. 9-15.
154. Kamei D, Yamakawa K, Takegoshi Y, et al. Reduced painhypersensitivity and inflammation in mice lacking microsomalprostaglandin E synthase-1. J Biol Chem. 2004; 279(32): p. 33684.
155. Mancini J, Blood K, Guay J, et al. Cloning, expression, and upregulationof inducible rat prostaglandin E synthase duringlipopolysaccharide-induced pyresis and adjuvant-induced arthritis J Biol Chem 2001; 276(6): p. 4469.
156. Stichtenoth D, Thoren S, Bian H, et al. Microsomal prostaglandinE synthase is regulated by proinflammatory cytokines andglucocorticoids in primary rheumatoid synovial cells. J Immunol 2001; 167(1): p. 469.
157. Claveau D, Sirinyan M, Guay J, et al. Microsomal prostaglandin Esynthase-1 is a major terminal synthase that is selectively upregulatedduring cyclooxygenase-2-dependent prostaglandin E2production in the rat adjuvant-induced arthritis model. J Immunol 2003;170(9): p. 4738.
158. Kojima F, Naraba H, Sasaki Y, et al. Prostaglandin E2 is anenhancer of interleukin 1 -induced expression of membraneassociated prostaglandin E synthase in rheumatoid synovialfibroblasts. Arthritis Rheum 2003;48(10): p. 2819-28.
159. Kojima F, Naraba H, Miyamoto S, et al. Membrane-associatedprostaglandin E synthase-1 is upregulated by proinflammatorycytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 2004; 6(4): p. R355-65.
160. Procházková M, Zanvit P, Doležal T, et al.Increased geneexpression and production of spinal cyclooxygenase 1 and 2 duringexperimental osteoarthritis pain. Physiol Res 2009; 58(3): p. 419-25.
161. Knorth H, Dorfmüller P, Lebert R, et al. Participation ofcyclooxygenase-1 in prostaglandin E2 release from synovitis tissuein primary osteoarthritis in vitro. Osteoarth Cartilage 2004; 12(8):p. 658-66.
162. Frean S, Bryant C, Froling I, et al. Nitric oxide production byequine articular cells in vitro. Equine Vet J 1997. 29(2): p. 98-102.
163. Tung J, Venta P, Caron J, Inducible nitric oxide expression inequine articular chondrocytes: effects of antiinflammatorycompounds. Osteoarth Cartilage 2002; 10(1): p. 5-12.
164. Espey M, Miranda K, Feelisch M, et al. Mechanisms of cell deathgoverned by the balance between nitrosative and oxidative stress. Ann NY Acad Sci 2000. 899: p. 209.
165. Dixon B. L, Subar A. F, Peters U, et al. Adherence to the USDA food guide, DASH eating plan, and Mediterranean dietary patternreduces risk of colorectal adenoma. J Nutr 2007; 137: p. 2443-50.
166. Bazoti F. N, Bergquist J, Markides K, et al. Localization of thenoncovalent binding site between amyloid-beta-peptide andoleuropein using electrospray ionization FT-ICR massspectrometry. Am Soc Mass Spectrom 2008; 19(8): p. 1078-85.
167. Carluccio M, Siculella L, Ancora M, et al. Olive oil and red wineantioxidant polyphenols inhibit endothelial activation:antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003;23(4): p. 622.
168. Fabiani R, De Bartolomeo A, Rosignoli P, et al. Virgin olive oilphenols inhibit proliferation of human promyelocytic leukemiacells (HL60) by inducing apoptosis and differentiation. J Nutr 2006; 136(3): p. 614.
169. Gill CI, Boyd A, McDermott E, et al. Potential anti-cancer effectsof virgin olive oil phenols on colorectal carcinogenesis models invitro. Int J Cancer 2005; 117(1): p. 1-7.
170. Hashim YZ, Rowland I, McGlynn H, et al. Inhibitory effects ofolive oil phenolics on invasion in human colon adenocarcinomacells in vitro. Int J Cancer 2008; 122: p. 495-500.
171. Fini L, Hotchkiss E, Fogliano V, et al. Chemopreventive propertiesof pinoresinol-rich olive oil involve a selective activation of theATM-p53 cascade in colon cancer cell lines. Carcinogenesis 2008;29(1): p. 139-46.
172. Tallarida RJ, Drug synergism and dose-effect data analysis. 2000,Florida: Chapman and Hall.
173. Lasekan J, Clayton M, Gendron-Fitzpatrick A, et al. Dietary oliveand safflower oils in promotion of DMBA-induced mammarytumorigenesis in rats. Nutr Cancer 1990. 13(3): p. 153-63.
174. Zusman I, GUREVICHI P, Madar Z, et al. Tumor-promoting andtumor-protective effects of high-fat diets on chemically inducedmammary cancer in rats. Anticancer res 1997. 17(1A): p. 349-56.
175. Llor X, Pons E, Roca A, et al. The effects of fish oil, olive oil, oleicacid and linoleic acid on colorectal neoplastic processes. Clin Nutr 2003;22(1): p. 71-9.
176. Laga A Zander, D Cagle, P, Prognostic significance ofcyclooxygenase 2 expression in 259 cases of non-small cell lungcancer. Arch Pathol Lab Med 2009; 129(9):p. 1113-7
177. Harris R, Beebe-Donk J, Alshafie G, Reduced risk of human lungcancer by selective cyclooxygenase 2 (COX-2) blockade: results ofa case control study. Int J Biol Sci 2007; 3(5): p. 328.
178. Boland G, Butt I, Prasad R, et al. COX-2 expression is associatedwith an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004; 90(2): p. 423-9.
179. Subbaramaiah K, Norton L, Gerald W, et al. Cyclooxygenase-2 isoverexpressed in HER-2/neu-positive breast cancer. J Biol Chem 2002; 277(21): p. 18649.
180. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance ofelevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62(3): p. 632.
181. Brown P, Subbaramaiah K, Salmon A, et al. Combinationchemoprevention of HER2/neu-induced breast cancer using a COX-2 inhibitor and an RXR-selective retinoid. Cancer Prev Res 2008; 1(3): p. 208.
182. Howe L, Subbaramaiah K, Patel J, et al. Celecoxib, a selectivecyclooxygenase 2 inhibitor, protects against human epidermalgrowth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002; 62(19): p. 5405.
183. Sandler R, Halabi S, Baron J, et al. A randomized trial of aspirin toprevent colorectal adenomas in patients with previous colorectalcancer. N Engl J Med 2003;348(10): p. 883.
184. Giardiello F, Yang V, Hylind L, et al. Primary chemoprevention offamilial adenomatous polyposis with sulindac. N Engl J Med 2002;346(14): p. 1054.
185. Steinbach G, Lynch P, Phillips R, et al. The effect of celecoxib, acyclooxygenase-2 inhibitor, in familial adenomatous polyposis. NEngl J Med 2000. 342(26): p. 1946.
186. De Lorgeril M, Salen P, Martin J, et al. Mediterranean diet,traditional risk factors, and the rate of cardiovascular complicationsafter myocardial infarction: final report of the Lyon Diet HeartStudy. Circulation 1999. 99(6): p. 779.
187. Martinez-Gonzalez M, Fernández-Jarne E, Serrano-Martínez M, etal. Mediterranean diet and reduction in the risk of a first acutemyocardial infarction: an operational healthy dietary score. Eur JClin Nutr 2002; 41(4): p. 153-60.
188. Fernandez-Jarne E, Martinez-Losa E, Prado-Santamaria M, et al. Risk of first non-fatal myocardial infarction negatively associatedwith olive oil consumption: a case-control study in Spain. Int JEpidemiol 2002; 31(2): p. 474-80.
189. Søndergaard E, Møller J, Egstrup K, Effect of dietary interventionand lipid-lowering treatment on brachial vasoreactivity in patientswith ischemic heart disease and hypercholesterolemia. Am Heart J 2003;145(5): p. 903.
190. Mezzano D, Leighton F, Martinez C, et al. Complementary effectsof Mediterranean diet and moderate red wine intake on haemostaticcardiovascular risk factors. Eur J Clin Nutr 2001; 55(6): p. 444-51.
191. Dell'Agli M, Fagnani R, Mitro N, et al. Minor components of oliveoil modulate proatherogenic adhesion molecules involved inendothelial activation. J Agric Food Chem 2006; 54(9): p. 3259-64.
192. Masella R, Giovannini C, Varì R, et al. Effects of dietary virginolive oil phenols on low density lipoprotein oxidation inhyperlipidemic patients. Lipids 2001; 36(11): p. 1195-202.
193. Gimeno E, Fito M, Lamuela-Raventos R. M, et al. Effect ofingestion of virgin olive oil on human low-density lipoproteincomposition. Eur J Clin Nutr 2002; 56(2): p. 114-20.
194. Plutzky J, Inflammatory pathways in atherosclerosis and acutecoronary syndromes. Am J Cardiol 2001; 88(8): p. 10-5.
195. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000. 102(8): p. 840.
196. Caughey G, Cleland L, Penglis P, et al. Roles of cyclooxygenase(COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesisby COX-2. J Immunol 2001; 167(5): p. 2831.
197. Baker C, Hall R, Evans T, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly inmacrophages. Arterioscler Thromb Vasc Biol 1999; 19(3): p. 646.
198. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2inhibition improves endothelial function in coronary artery disease. Circulation 2003;107(3): p. 405